<DOC>
	<DOCNO>NCT00622063</DOCNO>
	<brief_summary>To provide ongoing treatment ARQ 501 patient benefit prior treatment ARQ 501</brief_summary>
	<brief_title>An Extension Study Patients Previously Treated With ARQ 501</brief_title>
	<detailed_description />
	<mesh_term>Beta-lapachone</mesh_term>
	<criteria>Signed write inform consent Has previous participate clinical trial ARQ 501 eligible continue treatment Have receive previous treatment ARQ 501 treatment protocol Uncontrolled intercurrent illness , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>cancer , solid tumor</keyword>
</DOC>